Galanin receptor 1 (GALR1) maps to a common region of 18q loss in head and neck squamous cell carcinomas and is frequently inactivated by methylation. To investigate effects of GALR1 and its signaling pathways, we stably expressed hemaglutinin-tagged GALR1 in a human oral carcinoma cell line (UM-SCC-1-GALR1) that expresses no endogenous GALR1. In transfected cells, galanin induced activation of the extracellular-regulated protein kinase-1/2 (ERK1/2) and suppressed proliferation. Galanin stimulation mediated decreased expression of cyclin D1 and increased expression of the cyclin-dependent kinase inhibitors (CKI), p27
Introduction
Loss of heterozygosity (LOH) on chromosome 18q is associated with poor survival in head and neck cancer (Pearlstein et al., 1998) . Galanin receptor 1 (GALR1) (Cody et al., 1997) , a G protein-coupled receptor (GPCR), maps to the region of 18q loss (Takebayashi et al., 2000 . Furthermore, GALR1 is frequently silenced by methylation and deacetylation in head and neck squamous cell carcinomas (HNSCC) (Misawa et al., 2004) . Thus, we postulated that abnormalities of GALR1 might have functional consequences in HNSCC.
GPCRs and their ligands regulate multiple cellular functions, and some have been implicated in cancer cell growth, metastasis and apoptosis (Lahlou et al., 2003; Yang et al., 2005) . Galanin, is a 30 amino-acid neuropeptide (Tatemoto et al., 1983) that activates all three galanin receptors, GALR1, GALR2 and GALR3 (Berger et al., 2004; Lu et al., 2005) . Galanin and its receptors are abundant in the peripheral and central nervous system where they mediate diverse physiological activities (Branchek et al., 2000) . Wittau et al. (2000) reported that GALR2 initiates signaling in small-cell lung cancer via Gq, Gi and Gq 12 proteins. Berger et al. (2004) reported that exogenous expression of GALR2 inhibited cell proliferation and induced apoptosis in neuroblastoma cells, in contrast, GALR1 inhibited proliferation only. Henson et al. (2005) reported that GALR1 has antiproliferative effects in squamous carcinoma cells. However, others have reported that galanin receptors induce mitogenic signaling properties via extracellular-regulated protein kinase (ERK)1/2 (Seufferlein and Rozengurt, 1996) . GALR1 was reported to couple to heterotrimeric G proteins of the Gi type, which inhibit cAMP and stimulate mitogenactivated protein kinase (MAPK) via Gbg (Wang et al., 1998) . Thus, the role of galanin and GALR1-induced ERK1/2 activation and the mechanisms involved are not well established.
We studied the signaling contribution of GALR1 in a human oral carcinoma cell line that expresses neither galanin nor GALR1. We showed that GALR1 induces antiproliferation effects by a mechanism involving Gai activation of ERK1/2, and consequent regulation of cell cycle control proteins.
Results
Exogenous GALR1 expression does not affect GALR2 and GALR3 mRNA expression UM-SCC-1 cells express message for GALR2, and GALR3 but not GALR1 as determined by qualitative reverse transcriptase-polymerase chain reaction (RT-PCR) experiments (Figure 1a ). This is consistent with our findings that promoter hypermethylation silences GALR1 in these cells (Misawa et al., 2004) . Exogenous GALR1-hemaglutinin (HA) expression in UM-SCC-1-GALR1 was assessed by immunoblotting ( Figure 1b ) and immunofluorescence (Figure 1c ). GALR1-HA localized to the cytoplasmic membrane as expected for a GPCR (Figure 1c ). As expected, GALR1 expression in UM-SCC-1-GALR1 was significantly increased relative to UM-SCC-1-mock (Po0.01), but no significant differences in GALR2 and GALR3 expression were detected by quantitative RT-PCR (Figure 1d ). Thus, differences obtained with UM-SCC-1-GALR1 and UM-SCC-1-mock following galanin stimulation should reflect mainly the function of GALR1.
Galanin and GALR1 induce ERK1/2 activation without PI3K pathway stimulation To determine the GALR1 signaling pathway, we evaluated galanin and GALR1-mediated ERK1/2, protein kinase B (Akt) and S6 protein kinase (S6K) activation. ERK1/2 activation in UM-SCC-1-GALR1 was apparent at 0.3 h, increased to a peak level at 1-3 h and declined slowly through 24 h after stimulation (Figure 2a ). ERK1/2 phosphorylation intensity was normalized to epidermal growth factor (EGF)-induced ERK1/2 activation and was significantly stronger in UM-SCC-1-GALR1 than in UM-SCC-1-mock cells at all time points, 0.3, 12 and 24 h (Po0.05) and 1, 3 and 6 h (Po0.01) ( Figure 2a ). As shown in Figure 2b , both Akt and pS6K, downstream mediators of phosphatidylinositol 3-kinase (PI3K), were activated at all time points, but there were no significant differences between UM-SCC-1-GALR1 and UM-SCC-1-mock cells (Figure 2b ). Thus, GALR1 stimulates ERK1/2 activation but is not required for PI3K signaling in UM-SCC-1 cells. To determine if GALR2 influences ERK activation mediated by galanin and GALR1, galanin and a selective GALR2 agonist, GALP, were added simultaneously to UM-SCC-1 and UM-SCC-1-GALR1 cultures. GALP did not alter ERK activation (Figure 2c ), indicating that GALR1 is the primary receptor for activation of this pathway.
Galanin and GALR1 inhibit cell proliferation Figure 3a shows dose-and time-dependent proliferation assays after galanin treatment. As the galanin concentration increased, the cell number at 24 h decreased in UM-SCC-1-GALR1 but not in UM-SCC-1-mock cells (Po0.01). Furthermore, when the cells were treated with a fixed concentration of galanin (1 mM) and counted at 24, 48 and 72 h, the difference between UM-SCC-1-GALR1 and UM-SCC-1-mock cells was apparent at 24 h, and increased in a time-dependent manner (Po0.01). To clarify the mechanism of GALR1-induced inhibition of cell proliferation, we examined bromodeoxyuridine (BrdU) incorporation in UM-SCC-1-GALR1 and UM-SCC-1-mock cells. Compared with UM-SCC-1-mock cells, UM-SCC-1-GALR1 cells showed a significantly lower rate of BrdU incorporation after galanin treatment (Po0.01) (Figure 3b ). Addition of GALP did not alter the galanin-induced inhibition of cell proliferation (Figure 3c ).
Galanin and GALR1 downregulate cyclin D1 and upregulate p27
Kip1 and p57
Kip2
Tumor-associated alterations in cell proliferation frequently affect cyclin-dependent kinases (Cdks) and their regulators such as p27
Kip1
, p57 Kip2 and cyclin D1. As shown in Figure 4a , cyclin D1 expression decreased in galanin-treated UM-SCC-1-GALR1 but not in UM-SCC-1-mock cells. Densitometric measurements showed cyclin D1 expression was significantly suppressed (Po0.01). In contrast, p27
Kip1 and p57 Kip2 expression increased after galanin treatment in UM-SCC-1-GALR1, but not in UM-SCC-1-mock cells. Galanin also significantly enhanced both p27
Kip2 expression (Po0.01) (Figure 4b and c). These data suggest that GALR1-induced inhibition of proliferation is mediated by regulation of p27
, p57 Kip2 and cyclin D1.
Galanin and GALR1 induce active ERK1/2 and inhibit cell proliferation via the Gai pathway As GALR1 activates ERK1/2 and inhibits cell proliferation, we investigated if ERK1/2 activation is required for the inhibition of cell proliferation and determined the pathway used for this effect. U0126 and pertussis toxin (PTX) pretreatment each abrogated galanin-and GALR1-mediated ERK1/2 activation, whereas LY294002 did not, indicating that GALR1-induced ERK1/2 activation involves the PTX-sensitive Gai pathway, not the PI3K pathway linked to the Gbg subunit ( Figure 5a ). Similarly, U0126 and PTX each blocked galanin-induced GALR1-mediated cell growth inhibition, whereas LY294002 did not (Figure 5b ), indicating that cell growth inhibition also involves the PTX-sensitive Gai pathway. Thus, GALR1-induced ERK1/2 activation and cell growth inhibition are closely related. To verify the relationship between GALR1-induced ERK1/2 activation and cell growth inhibition, we assessed cyclin D1, p27 Kip1 and p57 Kip2 expression in galanin-treated UM-SCC-1-GALR1 with or without U0126. As shown in Figure 5c , p27
Kip2 expression increased significantly after galanin treatment, but this increase was abrogated by U0126 pretreatment. U0126 also abrogated the galanin-induced decrease in cyclin D1 expression. In each case, galanintreated UM-SCC-1-GALR1 exhibited a significant difference in cyclin D1, p27 Kip1 and p57 Kip2 expression when U0126-pretreated and untreated cells were compared. Thus, GALR1-mediated ERK1/2 activation, via stimulation of the Gi pathway rather than the PI3K pathway, contributes to regulation of cell cycle control proteins and growth inhibition.
Galanin and GALR1 inhibit colony formation and tumor growth in vivo As shown in Figure 6a , transient transfection of the parental UM-SCC-1 cells with pCMVGalanin resulted in galanin secretion (7.2 ng/ml) that is significantly higher than untransfected (0.16 ng/ml) or mock-transfected cells (0.19 ng/ml) (Po0.01). pCMVGalanin transfection significantly suppressed colony formation in UM-SCC-1-GALR1 cells (124.1 versus 51.4) (Po0.01). In UM-SCC-1-mock cells, pCMVGalanin or mock-transfection did not significantly affect colony formation (132.6 versus 168.4) (Figure 6b ). To assess the effect of GALR1 on in vivo tumor formation and growth, UM-SCC-1-GALR1 or UM-SCC-1-mock cells with or without pCMVGalanin transfection were injected subcutaneously (s.c.) into nude mice. Group 1 received UM-SCC-1-mock cells transfected with the pCMV empty vector. Group 2 received UM-SCC-1-GALR1 cells transfected with the pCMV empty vector. Group 3 received UM-SCC-1-mock cells transfected with pCMVGalanin and Group 4 received UM-SCC-1-GALR1 cells transfected with pCMVGalanin. As shown in Figure 6c , after s.c. injection, tumor formation rates of Group 1 (80%), 2 (70%) and 3 (70%) were significantly higher than Group 4 (30%) (Po0.05). In addition, the three tumors in Group 4 that did become established grew more slowly than those in the other three groups (Po0.05).
Discussion
Our previous work suggested that GALR1 might function as a tumor suppressor gene Henson et al., 2005) . Consistent with this hypothesis, the present study shows that GALR1 signaling can inhibit cell proliferation by a mechanism dependent on ERK1/2 activation. Furthermore, ERK1/ 2 activation leads to induction of p27 Kip1 , p57
Kip2 and to suppression of cyclin D1.
GALR1 is a classical Gi-coupled receptor (Wang et al., 1998) , and galanin is known to stimulate ERK1/2 activation (Seufferlein and Rozengurt, 1996) . Generally, the Gai pathway activates ERK1/2 by membrane recruitment of rap1GAP II and reduction of GTPbound Rap1 (Mochizuki et al., 1999) . Henson et al. (2005) observed that a blocking antibody to GALR1 activated ERK and inhibited growth in laryngeal cancer Figure 4 Galanin and GALR1 regulate cell cycle control genes. Serum-starved cells were treated with 1 mM galanin for 24 h as described and expression of cyclin D1 (a), p27
Kip1 (b) and p57 Kip2 (c) were assessed by immunoblotting. The band intensities were determined by densitometry and normalized to GAPDH. **Po0.01.
Galanin and GALR1 activate ERK1/2 but inhibit proliferation T Kanazawa et al cells. It was not clear in that study if GALR1 signaling activates or inhibits ERK1/2. In the present study, we demonstrated that galanin and GALR1-mediate PTXsensitive ERK1/2 activation using UM-SCC-1-GALR1 cells that express no endogenous GALR1. At one level, it is counterintuitive that activation of ERK1/2 by GALR1 could lead to an antiproliferative phenotype. However, antiproliferative effects consequent to ERK1/2 activation are known. Ferbeyre et al. (2002) showed that Ras could lead to cell-cycle arrest or cell death owing to activation of the MAPK/ERK kinase (MEK)/ERK pathway. Moreover, the small molecule UCN-01 induces cell cycle arrest by activation of the MEK/ERK pathway (Facchinetti et al., 2004) . Peptide-induced stimulation of ERK1/2 via other GPCRs including somatostatin type 2 (Lahlou et al., 2003) , b1 bradykinin (Dixon et al., 2002) and angiotensin II receptors (Otis et al., 2005) has also been linked to inhibition of cell proliferation. Thus, the galanin/ GALR1-induced antiproliferative effect consequent to ERK1/2 activation is not unprecedented. GALR1 has 30-34% protein homology with the somatostatin receptors (Branchek et al., 2000) and the latter inhibits cell proliferation through ERK2 activation (Lahlou et al., 2003) . The current study shows that galanin-and GALR1-induced growth inhibition is blocked by an Figure 5 The Gai pathway leads to ERK1/2 activation, cell growth inhibition and cell cycle control gene regulation. (a) Serumstarved UM-SCC-1-GALR1 cells were pretreated with U0126, PTX or LY294002 before galanin treatment, and evaluated for ERK1/2 phosphorylation. (b) Effect of galanin and signaling pathway inhibitors on cell proliferation. Serum-starved UM-SCC-1-GALR1 cells were pretreated with inhibitors before galanin treatment. Twenty-four hours later, the cells were counted **Po0.01. (c) Effects of galanin and ERK1/2 inhibition on cell cycle regulator proteins. Serum-starved UM-SCC-1-GALR1 cells were pretreated with U0126 before galanin treatment. Expression of cyclin D1, p27
Kip1 and p57 Kip2 were assessed as described in 'Materials and methods'. **Po0.01.
Galanin and GALR1 activate ERK1/2 but inhibit proliferation T Kanazawa et al ERK1/2-specific inhibitor and thus is dependent on ERK1/2 activation. The ultimate cellular response (i.e., growth inhibition versus proliferation) via the ERK1/2 pathway depends on the strength and duration of activation (Pumiglia and Decker, 1997) . Transient or modest activation may contribute to cell cycle progression, whereas sustained high levels and prolonged activation may result in growth arrest (Pumiglia and Decker, 1997; Tsukada et al., 2001; Dixon et al., 2002; Han et al., 2005) . The small GTP-binding proteins might be also important to determine the ultimate cellular response by ERK1/2 activation (Lahlou et al., 2003) . Woods et al. (1997) showed that expression of cyclin-dependent kinase inhibitors (CKI) such as p21 Cip1 versus activation of mitogenesis depends on the level of Ras activation. Modest levels of Ras activation stimulated mitogenesis, but higher levels led to an increase in CKI expression and mitogenic inhibition (Woods et al., 1997) . More recently, another Ras family member, Rap1 and its downstream effector B-Raf, were linked to ERK1/2 activation and consequent cell growth arrest and/or differentiation through a Ras-independent mechanism (Gendron et al., 2003; Lahlou et al., 2003) . Our data demonstrate that galanin and GALR1-mediated ERK1/2 activation increased 15-fold up to 3 h and remained above basal levels for 24 h. Lahlou et al. (2003) showed that the cellular decision to induce p27
Kip1 and G 1 cell cycle arrest is dictated by the cumulating effect of ERK1/2-dependent and ERK1/2-independent mitogenic effects. These findings support our data that galanin and GALR1 induce growth inhibition through ERK1/2 activation. In this study, galanin also stimulated the PI3K pathway in both UM-SCC-1-GALR1 and UM-SCC-1-mock, indicating that GALR2 or GALR3 mediates that effect. It is possible that heterodimers of the galanin receptors mediate the galanin effects we observed, however, addition of galaninlike peptide (GALP) did not affect ERK activation or cell growth inhibition (Figures 2c and 3c) , suggesting that GALR1 is the primary mediator of this pathway.
The ability of Gai protein to activate the ERK1/2 pathway is well documented (Mochizuki et al., 1999) . Although both the Gai-and the Gbg-dependent pathways can activate ERK1/2, the mechanism by which the ERK1/2 pathway can lead to inhibition of cell proliferation is not fully understood. Wang et al. (1998) showed that GALR1 couples to Gi but induces activation of MAPK activity via Gbg protein in Chinese hamster ovary cell line (CHO) cells. In our study, the involvement of Gai protein in GALR1-mediated ERK1/ 2 activation is based on the sensitivity of galanin-and GALR1-mediated ERK1/2 activation to PTX. PI3K can contribute to GPCR-mediated ERK1/2 activation by a mechanism involving Gbg subunits (Kranenburg and Moolenaar, 2001 ). In our data, the PI3K inhibitor LY294002 did not prevent either ERK1/2 activation or cell growth suppression induced by galanin and GALR1. The results indicate that GALR1 inhibits proliferation consequent to ERK1/2 activation via the Gai pathway, which is closely related to cell cycle arrest.
Furthermore, galanin and GALR1 regulated the expression of p27 Kip1 , p57
Kip2 and cyclin D1, and these effects were blocked by U0126 (Figure 5c ). p27
Kip2 are known as a tumor suppressor genes, and p27
Kip1 levels are associated with prognosis in many different tumors, including non-small-cell lung cell carcinoma, gastric carcinoma and laryngeal carcinoma (Esposito et al., 1997; Masuda et al., 2002; Hoffmann et al., 2005; Massarelli et al., 2005) . Overexpression of cyclin D1 occurs at a high frequency in a variety of carcinomas including those of breast, pancreas, and head and neck, and is associated with poor prognosis (Kong et al., 2000; Akervall et al., 2003) . The fact that galanin and GALR1 can regulate these genes suggests that GALR1 is a tumor suppressor in head and neck cancer cells.
Galanin and GALR1 also inhibit cell proliferation and suppress colony-forming potential. The suppression of colony formation might result from both growth inhibition and blockade of anchorage-independent survival by GALR1. As with the in vitro findings, tumor cells expressing both galanin and GALR1 have a reduced in vivo tumor formation rate and significantly decreased tumor growth in vivo.
In conclusion, we have shown that galanin and GALR1 induce a marked and prolonged ERK1/2 activation, upregulation of p27
Kip2
, downregulation of cyclin D1, and consequent inhibition of cell proliferation. These data support the concept that GALR1 is a likely tumor suppressor in head and neck cancer cells.
Materials and methods
Cell culture and proliferation assay UM-SCC-1, established from a human oral carcinoma, was cultured in Dulbecco's modified Eagle's Medium (Gibco, Grand Island, NY, USA) supplemented with 10% heatinactivated fetal bovine serum. The GALR1 sequence was obtained from a human cDNA library (Invitrogen, Carlsbad, CA, USA), C-terminal HA-tagged, and subcloned into the pcDNA3 vector (Invitrogen) containing an internal ribosomal entry site (Ires) and green fluorescent protein (GFP) sequence. The pCMVIresGFP vector was used as a transfection control. The UM-SCC-1-GALR1 and UM-SCC-1-mock cells were transfected with pCMVGALR1HAIresGFP or pCMVIresGFP, respectively, using lipofectamine (Invitrogen), and selected for GFP-positive cells. Twenty-four hours after plating, stably transfected cells were fed with serum-free medium (SFM) containing 0.1% bovine serum albumin for 24 h to induce quiescence. Then, the galanin (ANASPEC, San Jose, CA, USA) and in some experiments 1 mM (GALP) (Bachem Feinchemikalien AG, Bubendorf, Switzerland) were added. Activity of GALP was determined using GALR2-transfected UM-SCC-1 cells (data not shown). The ERK1/2 inhibitor U0126 or PI3K inhibitor LY294002 (Cell Signal Technology, Beverly, MA, USA) was added 1 h before galanin treatment. PTX (Sigma, St Louis, MO, USA) was added 10 h before treatment. Cell proliferation was measured by counting cells with a Coulter counter model Z1 (Beckman Coulter Inc., Hialeah, FL, USA). For the BrdU incorporation assay, the cells were incubated with 10 mM BrdU (Caltag Laboratories, Burlingame, CA, USA), and stained with mouse monoclonal anti-BrdU antibody (Caltag Laboratories) followed by Alexa Fluor 546 goat anti-mouse IgG 1 (Molecular Probes, Leiden, The Netherlands).
Qualitative and quantitative RT-PCR Total RNA was isolated using RNeasy mini kit (Qiagen Inc., Yalencia, CA, USA). Complementary DNA (cDNA) was synthesized according to the manufacturer's instructions. GALRs and b-actin were amplified using FastStart Taq DNA Polymerase (Roche Diagnostics GmbH, Penzberg, Germany) for Qualitative and LightCycler FastStart DNA Master SYBR Green I (Roche Diagnostics GmbH ) for quantitative RT-PCR. Primers were designed as follows: GALR1 forward, 5 0 -ctgcttctgctatgccaaggtc; reverse 5 0 -agga gattccaaacaccacaacc, GALR2 forward, 5 0 -agcatcctgacggtt gatgtgg; reverse, 5 0 -cccccaacaatgactccaactc, GALR3 forward, 5 0 -ctgatgcccagaacatttcactg, reverse, 5 0 -tgtgcccagcaggaagattagg. b-Actin forward, 5 0 -actatcggcaatgagcggtt, reverse, 5 0 -tgccacag gattccataccc.
Immunoblotting Cells were lysed with 0.1% Nonidet-P 40 lysis buffer containing protease (Calbiochem, La Jolla CA, USA) and phosphatase inhibitor cocktails (Sigma). Equal amounts of protein were electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred to Hybond-P (Amersham Biosciences, Buckinghamshire, UK). The membranes were incubated overnight with primary antibody at 41C, followed by incubation with anti-mouse or anti-rabbit secondary antibody horseradish peroxidase conjugate (Amersham Biosciences). Densitometric measurements of the bands were done using ChemiImager 4400 (Alpha Innotech, San Leandro, CA, USA). To avoid protein aggregation, cells lysates were treated with 1000 U of N-Glycosidase F (New England BioLabs, Beverly, MA, USA), and subjected to electrophoresis without boiling. The mouse monoclonal anti-HA tag antibody (Convance, Berkeley, CA, USA) was used as primary antibody to detect exogenous GALR1. ERK1/2, Akt and p70 S6K activation were evaluated with rabbit polyclonal phospho-ERK1/2, Akt or S6K antibody and total ERK1/2 or Akt antibody (Cell Signaling Technology). The expression of p27 Kip1 , p57
Kip2 and cyclin D1 were detected with murine monoclonal antibodies for p27 Kip1 , p57 Kip2 (Lab Vision, Fremont, CA, USA) and cyclin D1 (DakoCytomation Norden A/S, Glostrup, Denmark). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was detected by mouse monoclonal anti-GAPDH (Chemico International, Temecula, CA, USA) as an internal control for protein loading.
Immunocytochemistry
Cells were grown on coverslips for 24 h, fixed with 4% paraformaldehyde and stained with mouse monoclonal anti-HA tag antibody and Hoechst 33342 (Molecular Probes). Primary antibody binding was detected with Alexa Fluor 546 goat anti-mouse IgG 1 (Molecular Probes). The localization of exogenous GALR1 was determined using the Olympus FV-500 Confocal Microscope (Olympus Corporation, Tokyo, Japan).
Colony formation assay
A human galanin expression vector, pCMVGalanin, was constructed by subcloning the galanin precursor sequence, preprogalanin, obtained from human brain cDNA library. To confirm that the vector-induced galanin expression, UM-SCC-1 cells were transfected with pCMVGalanin and assessed for expression. Twenty-four hours after transfection, the cells were fed with SFM, and 24 h later, galanin secretion was measured by a human galanin-specific immunoassay kit (Peninsula Laboratories Inc, San Carlos, CA, USA). pCMVGalanin and a plasmid harboring the Hygromycin B resistance gene were cotransfected into UM-SCC-1-GALR1 or UM-SCC-1-mock cells cultured on 0.8% agarose-coated dishes. After the selection by Hygromycin B (Invitrogen), clonogenic survival was determined by crystal violet staining.
Tumor xenografts
To establish cell lines for animal experiments, the pCMVGalanin or empty vector were transfected into UM-SCC-1-GALR1 or UM-SCC-1-mock cells, followed by selection in Hygromycin B. Female BALB/c nude mice between the ages of 6-8 weeks (Charles River Laboratories Inc., Wilmington, MA, USA) were given s.c. injections of 5 Â 10 6 cells with 40% Matrigel (Collaborative Research, Bedford, MA, USA) into each flank. Tumor formation rates were determined as the percentages of persisting tumors of at least 1 mm 3 tumor volume after 4 weeks. Tumor size was measured periodically and volume calculated as 0.5 Â L Â W 2 , where L is the length (mm) and W is the width (mm). The relative tumor volume was calculated as the ratio of the growing tumor volume at any time to that of the minimum measured size of that tumor.
Statistical analysis
Results were tested for statistical significance using two-way analysis of variance or Student's t-test.
